MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
NAD Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
NAD+ (nicotinamide adenine dinucleotide) is not a peptide but an essential redox cofactor central to mitochondrial energy metabolism and to the activity of the sirtuin deacetylases (SIRT1-7), the PARP DNA-repair enzymes, and the CD38 ectoenzyme. Tissue NAD+ levels decline with age, and Imai, Sinclair and colleagues have argued that restoring NAD+ availability supports sirtuin-mediated genomic maintenance, mitochondrial biogenesis, and metabolic flexibility across multiple organ systems (PMID: 27508147). Direct intravenous, intramuscular, and subcutaneous NAD+ administration is used in research and integrative-medicine settings to bypass the intestinal degradation that limits oral NAD+, although precursors NMN and NR are more commonly studied in registered human trials with clinical endpoints (PMID: 30951076). Researchers study NAD+ supplementation for age-associated metabolic decline, mitochondrial myopathies, and recovery from cellular stress and chronic fatigue states.
Reconstitute: Add 3 mL bacteriostatic water → 166.7 mg/mL concentration.
Easy measuring: At 166.7 mg/mL, 1 unit = 0.01 mL = 1.667 mg (1667 mcg) on a U-100 insulin syringe.
Storage: Lyophilized powder frozen at −20 °C; reconstituted solution refrigerated at 2–8 °C for up to 14 days; protect from light.
Half-life: Plasma NAD+ half-life depends on route: intravenous infusion gives a sharp peak with redistribution into tissues within hours; intramuscular and subcutaneous routes give slower absorption and longer plasma exposure. Intracellular NAD+ pools turn over on minutes-to-hours timescales.
Route: Intravenous infusion (slow over 1-4 hours), intramuscular, or subcutaneous; oral NAD+ itself is largely degraded by the gut, so oral protocols use precursors NMN or NR rather than NAD+ directly.
Status: NAD+ is a dietary cofactor, not an FDA-approved drug. Parenteral NAD+ is compounded and used off-label; precursors NR and NMN are sold as supplements, and NMN has been the subject of FDA regulatory disputes over supplement status.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
Gently swirl or roll the vial until the powder fully dissolves (do not shake vigorously).
Inject slowly over 5–10 seconds to minimize tissue irritation; wait a few seconds before withdrawing the needle.
Interactive NAD Syringe Calculator
Currently visualizing the 500 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 500mg dry powder in 3mL water yields 166.67 mg/mL. To evaluate a 250mcg dose, pull to 0.1 units (0 syringe ticks).
U-100 Syringe Representation
0.1 Units (0 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 50 mg | 30 units (0.30 mL) |
| Week 2 | 75 mg | 45 units (0.45 mL) |
| Weeks 3–8 | 100 mg | 60 units (0.60 mL) |
| Weeks 9–12 | 100 mg | 60 units (0.60 mL) |
| Weeks 13–16 | 100 mg | 60 units (0.60 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 500 mg vial.
Peptide Vials (NAD+, 500 mg each):
- check8 weeks ≈ 11 vials (total 5,075 mg used)
- check12 weeks ≈ 16 vials (total 7,875 mg used)
- check16 weeks ≈ 22 vials (total 10,675 mg used)
Insulin Syringes (U‑100, 1 mL):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check8 weeks (11 vials): 33 mL → 4 × 10 mL bottles
- check12 weeks (16 vials): 48 mL → 5 × 10 mL bottles
- check16 weeks (22 vials): 66 mL → 7 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- check12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- check16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Mechanism of Action (MOA)
NAD+ is a pyridine nucleotide composed of nicotinamide and adenine linked via two ribose sugars and a pyrophosphate bridge. It serves as the central electron carrier in oxidative metabolism (NADH/NAD+ ratio drives the electron transport chain) and as the obligatory substrate for three major enzyme families: sirtuins (NAD-dependent deacetylases regulating gene expression, DNA repair, mitochondrial biogenesis, and metabolic flexibility), PARPs (DNA damage repair, particularly base excision and single-strand break repair), and CD38/CD157 (ectoenzymes that consume NAD+ for cyclic ADP-ribose signaling). Tissue NAD+ concentrations decline progressively with age across human and animal studies, with reductions of 30–60% by the seventh decade in muscle, brain, skin, and liver, attributable to a combination of reduced NAMPT-driven biosynthesis and increased CD38-driven consumption [2]. The age-related NAD+ decline contributes to mitochondrial dysfunction, impaired DNA damage repair, dysregulated metabolism, and chronic inflammation — features of multiple age-related pathologies. Sinclair, Imai, and others established the conceptual framework that restoring NAD+ levels by precursor supplementation could reverse aspects of age-related metabolic and cellular decline. NAD+ can be raised by oral supplementation with precursors entering the salvage pathway: nicotinamide riboside (NR) is phosphorylated by NRK1/2 to NMN and then converted to NAD+ by NMNATs; nicotinamide mononucleotide (NMN) is dephosphorylated by CD73 to NR for cell entry and then re-converted. Both oral NR and NMN have demonstrated dose-dependent NAD+ elevation in human peripheral blood mononuclear cells and skeletal muscle [4][5][6]. Direct NAD+ administration (parenteral) bypasses biosynthetic steps; intravenous NAD+ infusion delivers substrate directly to the bloodstream, although NAD+ does not freely cross cell membranes and likely requires conversion to NMN or NR by extracellular CD73 and CD38 enzymes before cellular uptake. Despite this biochemical complexity, IV NAD+ at 250–1000 mg infused over 1–4 hours has become a widely used integrative-medicine intervention for age-related fatigue, mitochondrial dysfunction, neurodegenerative symptom support, and addiction recovery — though controlled clinical evidence supporting these uses is limited. Subcutaneous and intramuscular NAD+ at 100–500 mg per dose is used in self-administered research-community protocols, typically several times per week in 4–6 week cycles. Oral NAD+ is poorly bioavailable; precursor oral supplementation (NR, NMN) is the evidence-supported strategy for raising tissue NAD+ in randomized clinical trials. Yoshino, Imai, and colleagues reported in Science 2021 that 250 mg/day NMN for 10 weeks improved muscle insulin sensitivity in prediabetic women [5]. Subsequent placebo-controlled trials of NMN at 125–500 mg/day and NR at 250–1000 mg/day showed sustained NAD+ elevation, modest improvements in aerobic capacity and arterial stiffness, and excellent tolerability in older adults [6][7].
Clinical Trial Efficacy Highlights
- starYoshino, Klein, Imai and colleagues randomized 25 prediabetic women to 250 mg/day NMN or placebo for 10 weeks. The NMN group showed significantly improved muscle insulin sensitivity (hyperinsulinemic-euglycemic clamp) and increased muscle NAD+ metabolites, demonstrating a metabolic benefit of NAD+ precursor supplementation in humans [5].
- starMartens and colleagues showed in a randomized crossover trial that 1000 mg/day nicotinamide riboside for 6 weeks in middle-aged and older adults safely doubled blood NAD+ levels and reduced systolic blood pressure and arterial stiffness in stage 1 hypertensive subjects [6].
- starIgarashi and colleagues reported in a 12-week double-blind RCT that 250 mg NMN twice daily elevated blood NAD+ metabolites and tended to reduce arterial stiffness markers in healthy middle-aged adults [7].
- starTrammell, Brenner and colleagues established that oral nicotinamide riboside at 100–1000 mg dose-dependently increases blood and skeletal muscle NAD+ in healthy humans with good tolerability and safety [4].
- starImai, Guarente, and colleagues established the molecular basis for NAD+ supplementation by demonstrating that the Sir2 protein is an NAD-dependent histone deacetylase, providing the foundational mechanism linking NAD+ availability to sirtuin-mediated longevity programs [3].
- starMills, Yoshino, Imai and colleagues showed in C57BL/6 mice that long-term NMN supplementation (100–300 mg/kg/day) mitigated age-related physiological decline including insulin sensitivity, lipid metabolism, mitochondrial function, and eye function [8].
- starClinical use of intravenous NAD+ at 250–1000 mg infused over 1–4 hours has been reported in addiction recovery and chronic fatigue protocols with anecdotal benefit, but controlled trial evidence for IV NAD+ in these indications remains limited and methodologically weak.
- starA systematic review of NAD+ supplementation across clinical trials confirmed consistent NAD+ elevation with oral precursors (NR, NMN) and favorable safety profile across doses up to 1000 mg/day, though benefits on hard clinical endpoints such as cardiovascular events or mortality remain to be established [1].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningOral NAD+ precursors (NR, NMN) are generally well tolerated at doses up to 1000 mg/day; the most common side effects are mild nausea, flushing, headache, and gastrointestinal upset, typically resolving with dose reduction.
- warningIntravenous NAD+ infusion can produce uncomfortable flushing, chest tightness, dyspnea, and abdominal discomfort during administration if infused too rapidly; slowing the infusion rate substantially mitigates these symptoms.
- warningSubcutaneous and intramuscular NAD+ injections may produce significant injection-site pain and induration, sometimes lasting hours; some users describe these injections as substantially more uncomfortable than typical peptide injections.
- warningAnxiety, restlessness, and palpitations have been reported during high-dose IV NAD+ infusions, possibly reflecting effects on adrenergic tone or rapid intracellular metabolic shifts; these usually resolve on slowing or pausing the infusion.
- warningTheoretical concerns about supraphysiologic NAD+ levels driving cancer growth in occult malignancy have not been borne out in published cohort data, but caution is warranted in patients with active or recent malignancy.
- warningDrug interactions are limited but include theoretical additive effects with metformin, sirtuin activators, and PARP inhibitors; clinical significance is unclear.
- warningPregnancy and lactation safety data for high-dose NAD+ supplementation are limited; routine prenatal niacin amounts are safe but pharmacologic doses are not recommended in pregnancy.
- warningLong-term safety of chronic supraphysiologic NAD+ supplementation beyond 1–2 years has not been formally characterized in randomized trials.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical NAD dosage?expand_more
Oral NMN dosing is typically 250–500 mg/day; oral NR dosing is 250–1000 mg/day. Intramuscular or subcutaneous NAD+ is typically 100–500 mg several times weekly in 4–6 week cycles. Intravenous NAD+ infusion is typically 250–1000 mg over 1–4 hours, once weekly.
How is NAD administered?expand_more
Oral precursors (NMN, NR) are the evidence-supported route. Parenteral NAD+ is administered by slow intravenous infusion (1–4 hours), subcutaneous injection, or intramuscular injection. Direct oral NAD+ has poor bioavailability and is generally inferior to precursor supplementation.
Can NAD be stacked?expand_more
NAD+ is commonly combined with sirtuin activators (resveratrol, pterostilbene), CD38 inhibitors, and senolytics in longevity research stacks. Combination of NR and pterostilbene (NRPT) has been studied in randomized trials and shown to elevate NAD+ levels safely and sustainably.
What are the side effects of NAD?expand_more
Oral precursors are generally well tolerated. IV NAD+ infusions can produce flushing, chest tightness, and dyspnea if infused too rapidly. Subcutaneous and IM injections may produce significant injection-site discomfort. No serious adverse events documented at typical research doses.
Is NAD FDA approved?expand_more
NAD+ injection is not FDA approved as a pharmaceutical for any indication. NAD+ precursors NR and NMN have FDA NDI status as dietary supplements but are not approved drugs. IV NAD+ in integrative medicine is provided off-label and is not FDA approved for any clinical indication.
Academic References & Study Citations
Radenkovic D, Reason, Verdin E. Clinical evidence for targeting NAD therapeutically. Pharmaceuticals (Basel). 2020;13(9):247. View Scientific Paper →
Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513-528. View Scientific Paper →
Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795-800. View Scientific Paper →
Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. View Scientific Paper →
Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. View Scientific Paper →
Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. View Scientific Paper →
Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. Nature NPJ Aging. 2022;8(1):5. View Scientific Paper →
Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806. View Scientific Paper →
Camacho-Pereira J, Tarrago MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127-1139. View Scientific Paper →
Dellinger RW, Santos SR, Morris M, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably. NPJ Aging Mech Dis. 2017;3:17. View Scientific Paper →